glp-1 obesity drug news october 2025 trends 2025: real-world data, patient outcomes & future therapies Poll: 1 in 8 Adults
Description
PLoS ONE 11(12):e0168396 Disclosures PB has acted as a consultant for Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Sanofi, Novo Nordisk and Horizon Pharma
Regular monitoring is important for people taking GLP-1 medication
Not just drugs, even gambling may be affected
We have examined seven ways these treatments improve health outcomes across multiple body systems
FDA Orange Book
Finding the right medication for weight loss: what to consider Lifestyle changes While the weight loss potential of GLP-1s is impressive, these results are not the outcome of medication alone
